Loading...
OTCMELTP
Market cap571mUSD
Dec 24, Last price  
0.54USD
1D
-2.72%
1Q
37.90%
Jan 2017
252.01%
IPO
30.50%
Name

Elite Pharmaceuticals Inc

Chart & Performance

D1W1MN
OTCM:ELTP chart
P/E
28.42
P/S
10.09
EPS
0.02
Div Yield, %
0.00%
Shrs. gr., 5y
4.62%
Rev. gr., 5y
49.55%
Revenues
57m
-99.83%
301,480550,6971,143,8411,413,1192,274,8253,344,2984,265,9632,424,1183,403,5254,601,3765,015,24612,498,3329,637,7157,458,7117,568,50817,994,63925,380,74932,262,11734,155,114,00056,625,128
Net income
20m
-99.54%
-5,906,890-6,883,914-11,803,512-13,893,060-6,604,708-8,056,874-13,582,159-15,058,2741,487,928-96,575,27128,929,674-683,0123,811,181-3,673,172-9,279,321-2,240,3515,088,4218,898,2454,409,902,00020,108,631
CFO
-3m
L
-4,883,503-4,625,549-8,314,268-9,834,277-4,540,068-1,364,7481,552,815-394,082-1,943,409-4,216,875-15,103,233-2,765,421-7,883,861-4,809,191-6,792,760-1,793,8213,193,8616,508,3143,338,704-3,281,558
Earnings
Feb 12, 2025

Profile

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and manufacture of oral, controlled-release products and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Products and New Drug Applications for Branded Products. It owns, licenses, and contract manufactures various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. The company also provides Oxycodone HCl immediate release 5mg, 10mg, 15mg, 20mg, and 30mg tablets for pains under Roxycodone brand; Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets for central nervous system diseases under the Adderall brand, as well as Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; SequestOX, an immediate release Oxycodone with Naltrexone; Loxapine Succinate capsules for treating antipsychotic under the brand Loxapine; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; and antibiotic products. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, and infection. Further, the company is developing a range of abuse deterrent opioid products. The company was incorporated in 1997 and is headquartered in Northvale, New Jersey.
IPO date
Feb 20, 2014
Employees
53
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑032015‑03
Income
Revenues
56,625
-99.83%
34,155,114
105,767.55%
32,262
27.11%
Cost of revenue
44,456
28,883,528
25,996
Unusual Expense (Income)
NOPBT
12,169
5,271,586
6,266
NOPBT Margin
21.49%
15.43%
19.42%
Operating Taxes
(19,646)
(424,028)
(1,736)
Tax Rate
NOPAT
31,814
5,695,614
8,002
Net income
20,109
-99.54%
4,409,902
49,459.23%
8,898
74.87%
Dividends
Dividend yield
Proceeds from repurchase of equity
159,921
39,325
14,353
BB yield
-101.26%
-133.87%
-40.64%
Debt
Debt current
5,020
326
557
Long-term debt
10,879
3,576
3,264
Deferred revenue
6
19
32
Other long-term liabilities
6,298
522
976
Net debt
8,793
(3,951)
(5,120)
Cash flow
Cash from operating activities
(3,282)
3,339
6,508
CAPEX
(810)
(5,737)
(499)
Cash from investing activities
(810)
(5,737)
(499)
Cash from financing activities
3,386
1,702
(667)
FCF
4,740
5,693,888
7,481
Balance
Cash
7,106
7,832
8,535
Long term investments
21
405
Excess cash
4,275
7,327
Stockholders' equity
(115,321)
(135,484)
(139,048)
Invested Capital
190,945
4,247,456
167,645
ROIC
1.43%
258.01%
4.79%
ROCE
16.09%
18,014.42%
21.91%
EV
Common stock shares outstanding
1,023,226
1,012,911
1,010,608
Price
0.15
432.21%
0.03
-17.02%
0.03
-42.70%
Market cap
157,925
437.63%
29,374
-16.84%
35,321
-38.60%
EV
166,718
25,423
30,201
EBITDA
13,640
5,272,931
7,700
EV/EBITDA
12.22
0.00
3.92
Interest
589
1,113
192
Interest/NOPBT
4.84%
0.02%
3.06%